Roivant Sciences Ltd. ROIV
Set alert
At close
Pre-market · Nov 2, 9:07 AM ET
- YTD
- +70.09%
- 1 year
- +84.64%
- Open
- 37.50
- Prev close
- 36.91
- Mkt cap
- 26.66B
- Vol
- 4.57M
- Avg vol
- 7.63M
- EPS
- -0.53
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 36.78
- High
- 37.94
- Forward P/E
- -21.49
- Beta
- 1.10
- Short ratio
- 5.65
- Inst. own
- 78.64%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 36.64
- 200-d avg
- 31.44
- 1y target
- 50.00
6M chart
Events in this range
- May 20, 2026Earnings: -0.2792; estimate -0.28931; surprise 3.49%
- Aug 6, 2026Earnings: -0.33; estimate -0.29962; surprise -10.14%
- Sep 8, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Sep 9, 2026Rating: Guggenheim · Buy → Buy
- Sep 9, 2026Rating: TD Cowen · Buy → Buy
- Sep 17, 2026Rating: Stifel · — → Buy
- Oct 12, 2026Downgrade: Wolfe Research · Outperform → Peer Perform
- Oct 28, 2026Rating: Citigroup · Buy → Buy
Signals (41)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 23, 2026 | 1 week ago |
| SMA: Bullish | Oct 21, 2026 | 1 week ago |
| MACD: Buy Signal | Oct 21, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 8, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 30, 2026 | 1 month ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| SMA: Bullish | Sep 28, 2026 | 1 month ago |
| SMA: Bearish | Sep 24, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 8, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 8, 2026 | 1 month ago |
| RSI: Overbought | Sep 8, 2026 | 1 month ago |
| SMA: Bearish | Aug 28, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 28, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 25, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jun 24, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 11, 2026 | 4 months ago |
| SMA: Bearish | Jun 10, 2026 | 4 months ago |
| SMA: Bullish | Jun 9, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 5 months ago |
| SMA: Bullish | Jun 3, 2026 | 5 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | May 20, 2026 | 5 months ago |
| MACD: Buy Signal | May 20, 2026 | 5 months ago |
| SMA: Bearish | May 19, 2026 | 5 months ago |
| MACD: Sell Signal | May 19, 2026 | 5 months ago |
| MACD: Buy Signal | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 8, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 4, 2026 | 6 months ago |
| SMA: Bearish | May 1, 2026 | 6 months ago |
Key statistics
- Market cap
- 26.66B
- Enterprise value
- 24.06B
- Trailing P/E
- 0.00
- Forward P/E
- -21.49
- PEG ratio
- 0.00
- Price / sales
- 3539.69
- Price / book
- 6.30
- EPS (TTM)
- -0.53
- Beta
- 1.10
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 7.53M
- Revenue growth
- -33.50%
- Free cash flow
- -1.12B
- Total cash
- 3.84B
- Total debt
- 107.15M
- Return on equity
- -8.52%
- Shares outstanding
- 722.32M
- Short % of float
- 7.56%
- 50-day average
- 36.64
- 200-day average
- 31.44
Analyst view
Consensus: strong buy
- Target (low)
- 41.00
- Target (mean)
- 50.00
- Target (high)
- 62.00
- Strong buy2
- Buy9
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.44866.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.36664 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.29962 | -0.33 | -0.03 | -10.14% |
| May 20, 2026 | Mar 31, 2026 | -0.28931 | -0.2792 | +0.01 | +3.49% |
| Feb 6, 2026 | Dec 31, 2025 | -0.29954 | -0.24 | +0.06 | +19.88% |
| Nov 10, 2025 | Sep 30, 2025 | -0.3198 | -0.20193 | +0.12 | +36.86% |
| Aug 11, 2025 | Jun 30, 2025 | -0.2497 | -0.25175 | 0.00 | -0.82% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | Citigroup | main | Buy | Buy |
| Oct 12, 2026 | Wolfe Research | down | Outperform | Peer Perform |
| Sep 17, 2026 | Stifel | init | — | Buy |
| Sep 9, 2026 | TD Cowen | main | Buy | Buy |
| Sep 9, 2026 | Guggenheim | main | Buy | Buy |
| Sep 8, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Roivant Sciences Ltd.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- roivant.com
News
- Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $56
- If You Invested $100 In Roivant Sciences Stock 5 Years Ago, You Would Have This Much Today
- Why Is Roivant Sciences Stock Surging Wednesday?
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
- This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
- Transcript: Roivant Sciences Q1 2027 Earnings Conference Call
- Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
- Immunovant Ends Autoimmune Skin Disorder Program
- Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint
Your note
Sign in to keep a note on ROIV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GLINE MATTHEW | Chief Executive Officer | Sale | Apr 15, 2026 | 16,736,100 |
| GOLD DANIEL ALLEN | Director | Sale | Jun 29, 2026 | 0 |
| KUMAR RAKHI | Officer | Conversion of Exercise of derivative security | Feb 12, 2025 | 163,264 |
| MANCHESTER KEITH S | Director | Stock Award(Grant) | Sep 15, 2026 | 1,753,460 |
| OREN ILAN | Director | Stock Award(Grant) | Oct 22, 2026 | 124,490 |
| PULIK RICHARD | Chief Financial Officer | Stock Award(Grant) | Apr 19, 2026 | 297,511 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 11.22% | 81,020,390 | 2.99B | Jun 29, 2026 |
| Blackrock Inc. | 6.68% | 48,236,091 | 1.78B | Jun 29, 2026 |
| Morgan Stanley | 5.90% | 42,592,905 | 1.57B | Jun 29, 2026 |
| QVT Financial LP | 3.28% | 23,723,074 | 875.62M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.06% | 22,123,198 | 816.57M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.00% | 21,641,339 | 798.78M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.19% | 23,009,528 | 849.28M | Aug 30, 2026 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 2.67% | 19,297,013 | 712.25M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.21% | 15,987,737 | 590.11M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.60% | 11,546,280 | 426.17M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Momentum ETF | 0.96% | 6,900,746 | 254.71M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 0.92% | 6,658,616 | 245.77M | Jun 29, 2026 |